
Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB:NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.
The FDA approval of the study's KAP protocol marks a first in the investigation of KAP for end-of-life patients and its potential to serve as a model of care for this difficult-to-treat population, the company said Thursday.